help button home button Am J Pathol Epitomics Buy 2 Antibodies Get 1 Free Special Offer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dias, P.
Right arrow Articles by Houghton, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dias, P.
Right arrow Articles by Houghton, P.
(American Journal of Pathology. 2000;156:399-408.)
© 2000 American Society for Investigative Pathology


Short Communications

Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass

Peter Dias*, Bin Chen{dagger}, Brad Dilday{dagger}, Hal Palmer{dagger}, Hajime Hosoi{ddagger}, Sujay Singh*, Chun Wu*, Xuo Li{dagger}, Joyce Thompson§, David Parham{dagger}, Stephen Qualman and Peter Houghton§

From the Department of Cell and Molecular Biology,*
Imgenex Corporation, San Diego, California; the Departments of Pathology and Laboratory Medicine and Pathology,{dagger}
University of Arkansas for Medical Sciences, Little Rock, Arkansas; the Department of Pediatrics,{ddagger}
Kyoto Prefectural University of Medicine, Kyoto, Japan; the Department of Molecular Pharmacology,§
St. Jude Children’s Research Hospital, Memphis, Tennessee; and the Pediatric Division,
Cooperative Human Tissue Network, Children’s Hospital, Columbus, Ohio

Rhabdomyosarcomas are a heterogeneous group of tumors with respect to their molecular basis, degree of differentiation, histology, and clinical behavior. Because of the wide variation of tumor morphology, it is often difficult to distinguish between the distinct subtypes of rhabdomyosarcomas. By using cryosections of tumor specimens and immunohistochemistry, in the present study we show that strong expression of myogenin in rhabdomyosarcoma is associated with alveolar histology (P = <0.0001, Fisher’s exact test). Although staining for myogenin was observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high levels of staining for myogenin, as defined by the frequency and intensity of staining of the tumor cells. The staining pattern suggests that the tumor cells are clonally derived from myogenin-positive progenitor cells. In contrast, most embryonal rhabdomyosarcomas (13 of 15) were either negative or showed a low level of staining for myogenin. In these tumors a larger proportion of tumor cells were distinctly negative for myogenin. Six of seven alveolar rhabdomyosarcomas that strongly stained for myogenin were also positive for Pax3–7/Forkhead (FKHR) by polymerase chain reaction/reverse transcriptase-polymerase chain reaction. One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts. Quantitative analysis for myogenin by Western blotting using a smaller subset of rhabdomyosarcomas revealed that in general there was a good correlation between immunohistochemical staining and Western blotting (P = 0.01, Pearson Correlation), although the former technique was more sensitive for detecting tumors with low levels of the protein. On average, alveolar rhabdomyosarcomas expressed at least threefold more myogenin than embryonal rhabdomyosarcomas. Our data show that staining for myogenin will be a simple, rapid, and accurate adjunct for distinguishing between alveolar and embryonal rhabdomyosarcomas. We propose that embryonal rhabdomyosarcomas result from an early block in myogenesis, before the expression of myogenin. In contrast, we propose that alveolar rhabdomyosarcomas either originate from a late block in myogenesis (after expression of myogenin) or that the pathological mechanisms involved in these neoplasms also induce strong expression of this protein.





This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
J.-J. Hu, A. Ambrus, T. W. Fossum, M. W. Miller, J. D. Humphrey, and E. Wilson
Time Courses of Growth and Remodeling of Porcine Aortic Media During Hypertension: A Quantitative Immunohistochemical Examination
J. Histochem. Cytochem., April 1, 2008; 56(4): 359 - 370.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J. S. Chamberlain, J. Metzger, M. Reyes, D. Townsend, and J. A. Faulkner
Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma
FASEB J, July 1, 2007; 21(9): 2195 - 2204.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Wachtel, T. Runge, I. Leuschner, S. Stegmaier, E. Koscielniak, J. Treuner, B. Odermatt, S. Behnke, F. K. Niggli, and B. W. Schafer
Subtype and Prognostic Classification of Rhabdomyosarcoma by Immunohistochemistry
J. Clin. Oncol., February 10, 2006; 24(5): 816 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura
Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo
J. Med. Genet., February 1, 2006; 43(2): 119 - 128.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
P. R.J. Bois, K. Izeradjene, P. J. Houghton, J. L. Cleveland, J. A. Houghton, and G. C. Grosveld
FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma
J. Cell Biol., September 12, 2005; 170(6): 903 - 912.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
N J Sebire and M Malone
Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas
J. Clin. Pathol., June 1, 2003; 56(6): 412 - 416.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
E. M. Brey, Z. Lalani, C. Johnston, M. Wong, L. V. McIntire, P. J. Duke, and C. W. Patrick Jr.
Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification
J. Histochem. Cytochem., May 1, 2003; 51(5): 575 - 584.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.